Novel Method for Producing Genetically Modified Measles Vaccine Viruses

Recombinant Measles Viruses – Vaccine Platform and Weapon against Cancer?

01-Dec-2022 - Genetically modified and attenuated measles vaccine viruses are considered a promising platform for research and development of vector vaccines and oncolytic measles viruses. The biotechnological production of these viruses is difficult, because it requires a precisely coordinated interaction of ...

EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million Transaction

ViraTherapeutics sale marks third exit from EMBL Ventures' current fund ETF II

14-Sep-2018 - EMBL Ventures announced that Boehringer Ingelheim has exercised its option to acquire EMBL Ventures' portfolio company ViraTherapeutics in a transaction with a total value of EUR 210 million (USD 245 million). The acquisition follows a collaboration and option agreement signed between ...

ORYX' Oncolytic Virus ParvOryx Successfully Completes Phase I/IIa Trial to Treat Glioblastoma Multiforme

16-Jun-2015 - ORYX announced the successful completion of the Phase I/IIa trial ParvOryx with the oncolytic parvovirus H1 to treat patients with progressive primary or recurrent glioblastoma. The open label, single center trial included 18 patients (UICC Stage IV), who showed recurrent or progressive disease ...

Using math to kill cancer cells

17-Jun-2013 - Here's a good reason to pay attention in math class. Nature Communications has published a paper from Ottawa researchers today, outlining how advanced mathematical modelling can be used in the fight against cancer. The technique predicts how different treatments and genetic modifications might ...

Can a virus fight cancer?

Canadian Cancer Society grants new funding

27-Jul-2012 - Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society. Viruses that selectively target and kill cancer cells — called oncolytic viruses — are an exciting new avenue for treating cancer because healthy ...

MediGene AG divests Oncolytic Herpes Simplex Viruses (oHSV) program to Catherex, Inc.

MediGene to receive a 40% stake in Catherex

13-Apr-2010 - MediGene AG announced that MediGene, Inc., its wholly owned subsidiary, has assigned its development program of oncolytic herpes simplex viruses (oHSV), to Catherex, Inc., a private US company located in Philadelphia, Pennsylvania. In return, MediGene receives a 40% stake in Catherex, making ...

Viralytics broadens IP portfolio

07-Nov-2008 - Viralytics Limited has received a Notice of Allowance from the United States Patent Office for its patent application covering the use of Echoviruses (including EVATAKTM) for the treatment of all cancers bearing expression of the integrin a2b1. EVATAKTM is the trade name for Viralytics’ ...

Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent

31-Jan-2008 - Oncolytics Biotech Inc. has been granted Canadian Patent 2,408,251 entitled "Clearance of Neoplastic Cells from Mixed Cellular Compositions using Viruses." The claims describe methods of selectively removing cancer cells ex vivo from blood stem cells and other organs using various viruses ...

MediGene: Dose-Finding Trial of Oncolytic Virus NV1020 for the Treatment of Liver Metastases Shows Efficacy Trends

19-Sep-2006 - MediGene AG announced that the interim analysis of the phase I/II trial of the cancer-killing virus NV1020 for the treatment of liver metastases in patients suffering from colorectal carcinoma has shown a clear indication of efficacy. Therefore the trial will be continued as scheduled, with the ...

Cell Genesys San Diego Manufacturing Operation Acquired by Genzyme

24-Nov-2005 - Cell Genesys, Inc. and Genzyme Corp. announced that Genzyme has acquired Cell Genesys' manufacturing operation in San Diego, CA to support the growth of Genzyme's gene therapy programs. Under the terms of the agreement, Genzyme will pay Cell Genesys $3.2 million in cash for the assets contained ...